Opdivo (Nivolumab)

Nivolumab, the active ingredient in Opdivo, is a monoclonal antibody presented as a sterile solution for intravenous infusion use. It is indicated for several advanced cancers and works by enhancing the body’s immune response against tumor cells.

GNH USA supplies Opdivo as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Opdivo is a PD‑1 checkpoint inhibitor used in the treatment of various malignancies. - Melanoma: improves overall survival in patients with unresectable or metastatic disease. - Non‑small cell lung cancer: used as first‑line therapy in combination with chemotherapy for advanced disease. - Renal cell carcinoma: extends survival in patients with advanced clear‑cell carcinoma. - Classical Hodgkin lymphoma: provides durable responses in relapsed or refractory cases. - Head and neck squamous cell carcinoma: enhances response rates when combined with chemotherapy.

Adverse reactions to Opdivo can vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Rash: mild to moderate skin eruptions. - Pruritus: itching without visible rash. - Diarrhea: loose stools of varying intensity. - Nausea: occasional upset stomach. - Infusion‑related reactions: transient symptoms during administration.

Serious or Rare Side Effects: - Immune‑mediated pneumonitis: inflammation of lung tissue. - Colitis: severe inflammation of the colon. - Hepatitis: liver inflammation leading to elevated enzymes. - Endocrinopathies (e.g., hypophysitis): hormone‑axis disturbances. - Nephritis: kidney inflammation. - Severe skin reactions (e.g., Stevens‑Johnson syndrome).

Patients receiving Opdivo should be monitored closely for immune‑related toxicities and overall clinical status. - Monitor for immune‑related adverse events: assess organ function regularly. - Evaluate baseline and periodic laboratory values: liver enzymes, renal function, thyroid hormones. - Manage infusion reactions promptly: have emergency medications available. - Avoid live vaccines during treatment: risk of infection is increased. - Discontinue or pause therapy for grade 3‑4 toxicities: follow established guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Opdivo may interact with other agents that affect the immune system or share overlapping toxicities.

Major Interactions (Avoid): - Concurrent use with other immune checkpoint inhibitors: heightened risk of severe immune reactions. - Live attenuated vaccines: contraindicated due to immunosuppression. - High‑dose systemic steroids used for other conditions: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy given concurrently: monitor for additive hematologic toxicity. - Corticosteroids administered for adverse‑event management: adjust dosing as needed. - Anticoagulants or antiplatelet agents: watch for bleeding if thrombocytopenia occurs. - Other immunosuppressive agents (e.g., azathioprine): may blunt immune response.